Economic consequences of selective serotonin reuptake inhibitor use with drugs also metabolized by the cytochrome P-450 system

Clinical Therapeutics

Volumn 20, Issue 4, 1998, Pages 780-796

  Ozminkowski, Ronald J ^a   Hylan, Timothy R ^b,c,d   Melfi, Catherine A ^b,e,f   Meneades, Laurie M ^a   Crown, William H ^a   Croghan, Thomas W ^b,c,f   Robinson, Rebecca L ^f  

^a MEDSTAT GROUP   (United States)

^b ELI LILLY AND COMPANY   (United States)

^c INDIANA UNIVERSITY   (United States)

^d MIAMI UNIVERSITY   (United States)

^e REGENSTRIEF INSTITUTE   (United States)

^f INDIANA UNIVERSITY   (United States)

Author keywords

Antidepressants; Clinical outcomes; Cytochrome P 450 system; Drug interactions; Health care expenditures; Selective serotonin reuptake inhibitors

Indexed keywords

ALPRENOLOL; AMIODARONE; ASTEMIZOLE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BUFURALOL; CALCIUM CHANNEL BLOCKING AGENT; CYTOCHROME P450 ISOENZYME; DILTIAZEM; ERYTHROMYCIN; FELODIPINE; FLUOXETINE; METOPROLOL; MEVINOLIN; NICARDIPINE; NITRENDIPINE; PAROXETINE; PROPRANOLOL; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TERFENADINE; TIMOLOL; VERAPAMIL;

ADULT; AGED; ARTICLE; DEPRESSION; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HEALTH CARE COST; HEALTH ECONOMICS; HUMAN; MAJOR CLINICAL STUDY; MALE; MEDICAL RECORD; PRESCRIPTION; TREATMENT OUTCOME;

EID: 0031709259     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/S0149-2918(98)80141-0     Document Type: Note

References (38)

1. Kaplan HI, Sadock BJ, Grebb JA. Kaplan and Sadock's Synopsis of Psychiatry. 7th ed. Philadelphia: Williams & Wilkins; 1994;976-981.
2. Mitchell PB. Selective serotonin reuptake inhibitors: Adverse effects, toxicity, and interactions. Adverse Drug React Toxicol Rev. 1994;13:121-144.
3. Depression Guidelines Panel. Depression in Primary Care, Volume 2. Treatment of Major Depression. Clinical Practice Guideline Number 5. AHCPR publication no. 93-0552. Rockville, Md: Agency for Health Care Policy and Research, US Department of Health and Human Services, Public Health Service; 1993.
4. Nemeroff CB, DeVane CL, Pollock BG. Newer antidepressants and the CYP450 system. Am J Psychiatry. 1996;153(Suppl 3):311-320.
5. Mitchell PB. Drug interactions of clinical significance with selective serotonin reuptake inhibitors. Drug Saf. 1997; 17: 390-406.
6. Preskorn SH. Targeted psychotherapy in depression management: Comparative pharmacokinetics of fluoxetine, paroxetine, and sertraline. Int Clin Psychopharmacol. 1994;8(Suppl 3):13-19.
7. Nelson JC, Mazure CM, Bowers MB, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48: 303-307.
8. Potter WZ, Rudorfer MV, Monji H. The pharmacologic treatment of depression. NEJM. 1991;325:633-642.
9. Harvey AT, Preskorn SH. Cytochrome P450 enzymes: Interpretation of their interactions with selective serotonin reuptake inhibitors. Part I. J Clin Psychopharmacol. 1996;16:273-285.
10. Spina E, Perucca E. Newer and older antidepressants: A comparative review of drug interactions. CNS Drugs. 1994;2: 479-497.
11. Roth A, Akyol S, Nelson JC. Delirium associated with the combination of a neuroleptic, an SSRI, and benztropine. J Clin Psychiatry. 1994;55:492-495.
12. Rothschild AJ. Delirium: An SSRI-benztropine effect? J Clin Psychiatry. 1995;56:537. Letter.
13. Rapeport WG, Coates PE, Dewland PM, Forster PL. Absence of a sertraline-mediated effect on digoxin pharmacokinetics and electrocardiographic findings. J Clin Psychiatry. 1996;57(Suppl 1):16-19.
14. Askinazi C. SSRI treatment of depression with comorbid cardiac disease. Am J Psychiatry. 1996;153:135-136.
15. Evans ME, Kortas KJ. Potential interaction between isoniazid and selective serotonin reuptake inhibitors. Am J Health-Syst Pham. 1995;52:2135-2136. Letter.
16. Leung M, Ong M. Lack of an interaction between sumatriptan and selective serotonin reuptake inhibitors. Headache. 1995;35:488-489.
17. Taylor D. Selective serotonin reuptake inhibitors and tricyclic antidepressants in combination: Interactions and therapeutic uses. Br J Psychiatry. 1995;167:575-580.
18. Weilberg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressant converts non-responders to responders: A preliminary report. J Clin Psychiatry. 1989;50:447-449.
19. Seth R, Jennings AL, Bindman J, et al. Combination treatment with noradrenaline and serotonin reuptake inhibitors in resistant depression. Br J Psychiatry. 1992;161:562-565.
20. Cowen PJ, Power AC. Combination treatment of depression. Br J Psychiatry. 1993; 162:266-267.
21. Gregor KJ, Way K, Young CH, James SP. Concomitant use of selective serotonin re-uptake inhibitors with other cytochrome P450 2D6 and 3A4 metabolized medications: How often does it really happen? J Affect Disord. 1997;46:59-67.
22. Johnson JA, Bootman JL. Drug-related morbidity and mortality. Arch Intern Med. 1995;155:1949-1956.
23. Avom J. Putting adverse drug events into perspective. JAMA. 1997;277:341-342.
24. Bates DW, Spell N, Cullen DJ, et al. The costs of adverse drug events in hospitalized patients. JAMA. 1997;277:307-311.
25. Classen DC, Pestotnik SL, Evans S, et al. Adverse drug events in hospitalized patients. JAMA. 1997;277:301-306.
26. DeVane CL. Pharmacogenetics and drug metabolism of newer antidepressant agents. J Clin Psychiatry. 1994;55(Suppl 12):38-45.
27. Otton SV, Dafang W, Jopffe RT, et al. Inhibition by fluoxetine of cytochrome P4502D6 activity. Clin Pharmacol Ther. 1993;53:401-409.
28. Zajecka J, Tracy KA, Mitchell S. Discontinuation symptoms after treatment with serotonin reuptake inhibitors: A literature review. J Clin Psychiatry. 1997;58: 291-297.
29. Price JS, Waller PC, Wood SM, MacKay AV. A comparison of the post-marketing safety of four selective serotonin re-up-take inhibitors including the investigation of symptoms occurring on withdrawal. Br J Clin Pharmacol. 1996;42:757-763.
30. Rosenbaum JF, Fava M, Hoog SL, et al. Selective serotonin reuptake inhibitor discontinuation syndrome: A randomized clinical trial. Biol Psychiatry. 1998;44: 77-87.
31. Averill RF. Development. In: Fetter PB, Brand DA, Gamache D, eds. DRGs: Their Design and Development. Ann Arbor, Mich: Health Administration Press; 1991: 28-56.
32. Heckman JJ. The common structure of statistical models of truncation, sample selection, and limited dependent variables, and a simple estimator for such models. Ann Econ Soc Measure. 1976;5:475-492.
33. Crown W, Hylan T, Meneades L. Antidepressant selection and use and health care expenditures. PharmacoEconomics. 1998; 13:435-448.
34. Murnane RJ, Newstead S, Olsen RJ. Comparing public and private schools: The puzzling role of selectivity bias. J Business Econ Stat. 1985;3:23-35.
35. Halverson R, Palmquist R. Interpretation of dummy variables in semilogarithmic equations. Am Econ Rev. 1980;70: 474-475.
36. Sclar DA, Robison LM, Skaer TL, et al. Antidepressant pharmacotherapy: Economic evaluation of fluoxetine, paroxetine, and sertraline in a health maintenance organization. J Int Med Res. 1995;23: 365-412.
37. Hylan TR, Crown WH, Meneades L, et al. SSRI and TCA antidepressant selection and health care costs: A multivariate analysis. J Affect Disord. 1998;47:71-79.
38. Croghan TW, Lair TJ, Engelhart L, et al. Effect of antidepressant therapy on health care utilization and costs in primary care. Psychiatr Serv. 1997;48:1420-1426.